|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C07K 16/28 | (2006.01) |
| C07K2317/24 | (2013.01) | ||
| A61K 39/395 | (2006.01) | ||
| C07K2317/52 | (2013.01) | ||
| A61P 21/00 | (2006.01) | ||
| C07K2317/71 | (2013.01) | ||
| A61P 21/04 | (2006.01) | ||
| C07K2317/94 | (2013.01) | ||
| A61P 25/00 | (2006.01) | ||
| C07K 16/2875 | (2013.01) | ||
| A61P 25/16 | (2006.01) | ||
| A61P 1/04 | (2018.01) | ||
| A61P 13/12 | (2018.01) | ||
| A61P 25/28 | (2006.01) | ||
| A61P 29/00 | (2006.01) | ||
| A61P 17/00 | (2018.01) | ||
| A61P 19/02 | (2018.01) | ||
| A61P 37/02 | (2006.01) | ||
| A61P 21/00 | (2018.01) | ||
| A61P 21/02 | (2018.01) | ||
| A61P 21/04 | (2018.01) | ||
| A61P 25/00 | (2018.01) | ||
| A61P 25/16 | (2018.01) | ||
| A61P 25/28 | (2018.01) | ||
| A61P 29/00 | (2018.01) | ||
| A61P 37/02 | (2018.01) | ||
| A61P 37/06 | (2018.01) | ||
| A61P 7/04 | (2018.01) | ||
| A61P 9/10 | (2018.01) | ||
| A61P 3/10 | (2018.01) |
| (11) | Number of the document | 3253412 |
| (13) | Kind of document | T |
| (96) | European patent application number | 16747111.9 |
| Date of filing the European patent application | 2016-02-02 | |
| (97) | Date of publication of the European application | 2017-12-13 |
| (45) | Date of publication and mention of the grant of the patent | 2022-03-23 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2016/016165 |
| Date | 2016-02-02 |
| (87) | Number | WO 2016/126702 |
| Date | 2016-08-11 |
| (30) | Number | Date | Country code |
| 201562111261 P | 2015-02-03 | US |
| (72) |
LINCECUM, John, M. , US
JIANG, Bingbing , US
PERRIN, Steven, N. , US
GILL, Alan , US
GILL, Cynthia, A. , US
VIEIRA, Fernando G. , US
|
| (73) |
ALS Therapy Development Institute ,
480 Arsenal Street, Suite 201, Watertown, MA 02472,
US
|
| (54) | ANTI-CD40L ANTIBODIES AND METHODS FOR TREATING CD40L-RELATED DISEASES OR DISORDERS |
| ANTI-CD40L ANTIBODIES AND METHODS FOR TREATING CD40L-RELATED DISEASES OR DISORDERS |